MaxCyte, Inc. (NASDAQ:MXCT) Receives Average Rating of “Hold” from Analysts

MaxCyte, Inc. (NASDAQ:MXCT) has been assigned a consensus rating of “Hold” from the five analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 1 year target price among brokerages that have covered the stock in the last year is $5.50.

Several analysts have issued reports on MXCT shares. Craig Hallum cut their price objective on MaxCyte from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, March 25th. Wall Street Zen upgraded MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MaxCyte in a report on Friday, April 24th.

MaxCyte Trading Up 3.5%

NASDAQ MXCT opened at $1.19 on Wednesday. The stock’s 50-day moving average price is $0.93 and its two-hundred day moving average price is $1.08. The company has a market cap of $127.47 million, a PE ratio of -3.22 and a beta of 1.48. MaxCyte has a 1 year low of $0.64 and a 1 year high of $2.38.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.06. The firm had revenue of $6.22 million for the quarter, compared to the consensus estimate of $7.28 million. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%. Research analysts forecast that MaxCyte will post -0.3 EPS for the current fiscal year.

Institutional Trading of MaxCyte

Institutional investors and hedge funds have recently bought and sold shares of the stock. Capricorn Fund Managers Ltd acquired a new position in shares of MaxCyte in the 1st quarter valued at about $5,760,000. Mirabella Financial Services LLP increased its holdings in shares of MaxCyte by 24.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 8,200,000 shares of the company’s stock valued at $12,956,000 after purchasing an additional 1,600,000 shares during the period. State Street Corp increased its holdings in shares of MaxCyte by 4.0% in the 4th quarter. State Street Corp now owns 2,358,384 shares of the company’s stock valued at $3,655,000 after purchasing an additional 91,534 shares during the period. AXA S.A. increased its holdings in shares of MaxCyte by 123.2% in the 2nd quarter. AXA S.A. now owns 2,202,378 shares of the company’s stock valued at $4,801,000 after purchasing an additional 1,215,481 shares during the period. Finally, Brooklands Fund Management Ltd acquired a new position in shares of MaxCyte in the 1st quarter valued at about $1,538,000. Institutional investors and hedge funds own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.